Jiangsu Hengrui Pharmaceuticals (SHA:600276) said its contrast agent Ioversol injection was included in China's list of national essential medicines, effective Sept. 1.
The drug is indicated for cardiovascular angiography, contrast-enhanced computed tomography scans and excretory urography, according to a weekend filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade.